Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 17, 2021 - Issue 1
Submit an article Journal homepage
1,026
Views
0
CrossRef citations to date
0
Altmetric
Letter

Response to Shami et al. ‘Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single dose vaccination strategy for adults in Hong Kong’ (Hum Vacc Immunother 2020)

Ulrike K. Buchwalda CR, Merck & Co., Inc, Upper Gwynedd, PA, USA
,
Temitope Folaranmib GMA, Merck & Co., Inc.,Upper Gwynedd, PA, USA
&
Thomas Weissc CORE, Merck & Co., Inc.,Upper Gwynedd, PA, USACorrespondence[email protected]
Pages 173-175 | Received 20 Dec 2019, Accepted 29 Feb 2020, Published online: 02 Jul 2020

References

  • Shami JJP, Pathadka S, Chan EW, Hui J, Sato R, Patil S, Li X. Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single-dose vaccination strategy for adults in Hong Kong. Hum Vaccin Immunother. 2020;1–8. doi:10.1080/21645515.2019.1711300.
  • Ortqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M, Lindblad I, Sundelöf B, Kalin M. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet. 1998;351(9100):399–403. doi:10.1016/S0140-6736(97)07358-3.
  • Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One. 2017;12(1):e0169368. doi:10.1371/journal.pone.0169368.
  • Scott JA, Hall AJ, Leinonen M. Validation of immune-complex enzyme immunoassays for diagnosis of pneumococcal pneumonia among adults in Kenya. Clin Diagn Lab Immunol. 2000;7(1):64–67. doi:10.1128/CDLI.7.1.64-67.2000.
  • Musher DM, Mediwala R, Phan HM, Chen G, Baughn RE. Nonspecificity of assaying for IgG antibody to pneumolysin in circulating immune complexes as a means to diagnose pneumococcal pneumonia. Clin Infect Dis. 2001;32(4):534–38. doi:10.1086/318709.
  • Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928.
  • Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325(21):1453–60. doi:10.1056/NEJM199111213252101.
  • Evers SM, Ament AJ, Colombo GL, Konradsen HB, Reinert RR, Sauerland D, Wittrup-Jensen K, Loiseau C, Fedson DS. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis. 2007;26(8):531–40. doi:10.1007/s10096-007-0327-z.
  • Smith KJ, Zimmerman RK, Lin CJ, Nowalk MP, Ko F-S, McEllistrem MC, Roberts MS. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine. 2008;26(11):1420–31. doi:10.1016/j.vaccine.2008.01.007.
  • Food and Drug Administration. PNEUMOVAX® 23 (pneumococcal vaccine polyvalent). 1986.
  • Food and Drug Administration. PREVNAR 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]). 2019.
  • Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, Ishida M, Hamaguchi S, Aoshima M, Ariyoshi K. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017;17(3):313–21. doi:10.1016/S1473-3099(17)30049-X.
  • Robert Koch-Institut. Recommendations of the Standing Committee on Vaccination(STIKO) at the Robert Koch Institute – 2017/2018. 2017. https://www.rki.de/EN/Content/infections/Vaccination/recommandations/34_2017_engl.pdf?__blob=publicationFile.
  • Falkenhorst G, Remschmidt C, Harder T, Wichmann O, Glodny S, Hummers-Pradier E, Ledig T, Bogdan C. Background paper to the updatedpneumococcal vaccinationrecommendation for older adultsin Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016;59(12):1623–57.
  • Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AMM, Sanders EAM, Verheij TJM, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–25. doi:10.1056/NEJMoa1408544.
  • World Health Organization. WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
  • Stoecker C, Kobayashi M, Matanock A, Cho BH, Pilishvili T. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program. Vaccine. 2020;38(7):1770–77. doi:10.1016/j.vaccine.2019.12.029.
  • Heo JY, Seo YB, Choi WS, Lee J, Noh JY, Jeong HW, Kim WJ, Kim MJ, Lee HY, Song JY, et al. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. PLoS One. 2017;12(5):e0177342. doi:10.1371/journal.pone.0177342.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.